These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29183632)

  • 41. Pulmonary Fibrosis Foundation Summit 2015.
    Furlow B
    Lancet Respir Med; 2016 Jan; 4(1):13. PubMed ID: 26673676
    [No Abstract]   [Full Text] [Related]  

  • 42. Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.
    Maher TM; Swigris JJ; Kreuter M; Wijsenbeek M; Cassidy N; Ireland L; Axmann J; Nathan SD
    Respiration; 2018; 96(6):514-524. PubMed ID: 30114692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis.
    Togami K; Kanehira Y; Tada H
    Biol Pharm Bull; 2013; 36(10):1525-7. PubMed ID: 24088250
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
    Sathiyamoorthy G; Sehgal S; Ashton RW
    South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
    Loveman E; Copley VR; Scott DA; Colquitt JL; Clegg AJ; O'Reilly KM
    BMC Pulm Med; 2015 Apr; 15():37. PubMed ID: 25927225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDA panel likes new treatment for idiopathic pulmonary fibrosis.
    Morrow T
    Manag Care; 2010 Apr; 19(4):53-4. PubMed ID: 20446566
    [No Abstract]   [Full Text] [Related]  

  • 47. Idiopathic pulmonary fibrosis.
    Dempsey OJ; Miller D
    BMJ; 2013 Nov; 347():f6579. PubMed ID: 24201334
    [No Abstract]   [Full Text] [Related]  

  • 48. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs.
    Kingwell K
    Nat Rev Drug Discov; 2014 Jul; 13(7):483-4. PubMed ID: 24981347
    [No Abstract]   [Full Text] [Related]  

  • 49. A new era of drug therapy for idiopathic pulmonary fibrosis.
    Crooks MG; Hart SP
    Lancet Respir Med; 2014 Dec; 2(12):964-6. PubMed ID: 25466348
    [No Abstract]   [Full Text] [Related]  

  • 50. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
    Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
    Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
    Spagnolo P; Maher TM; Richeldi L
    Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.
    Kreuter M; Bonella F; Wijsenbeek M; Maher TM; Spagnolo P
    Biomed Res Int; 2015; 2015():329481. PubMed ID: 26779535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis.
    Miyamoto A; Morokawa N; Takahashi Y; Ogawa K; Takeyasu M; Murase K; Hanada S; Uruga H; Mochizuki S; Takaya H; Kurosaki A; Kishi K
    Intern Med; 2016; 55(6):657-61. PubMed ID: 26984086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Idiopathic pulmonary fibrosis: treatment with pirfenidone].
    Cano-Jiménez E
    Arch Bronconeumol; 2012 Oct; 48 Suppl 2():16-8. PubMed ID: 23630972
    [No Abstract]   [Full Text] [Related]  

  • 55. Idiopathic pulmonary fibrosis: A guide for nurse practitioners.
    Vega-Olivo M; Criner GJ
    Nurse Pract; 2018 May; 43(5):48-54. PubMed ID: 29465476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies.
    Lunardi F; Pezzuto F; Vuljan SE; Calabrese F
    Arch Pathol Lab Med; 2018 Sep; 142(9):1090-1097. PubMed ID: 30141997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.
    Loeh B; Drakopanagiotakis F; Bandelli GP; von der Beck D; Tello S; Cordani E; Rizza E; Barrocu L; Markart P; Seeger W; Guenther A; Albera C
    Am J Respir Crit Care Med; 2015 Jan; 191(1):110-3. PubMed ID: 25551350
    [No Abstract]   [Full Text] [Related]  

  • 58. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF.
    Milger K; Kneidinger N; Neurohr C; Reichenberger F; Behr J
    Eur Respir J; 2015 Oct; 46(4):1217-21. PubMed ID: 26341986
    [No Abstract]   [Full Text] [Related]  

  • 60. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
    Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
    Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.